WO2018110756A1 - Dispositif de surveillance de glycémie basé sur l'adénosine triphosphate - Google Patents

Dispositif de surveillance de glycémie basé sur l'adénosine triphosphate Download PDF

Info

Publication number
WO2018110756A1
WO2018110756A1 PCT/KR2016/015345 KR2016015345W WO2018110756A1 WO 2018110756 A1 WO2018110756 A1 WO 2018110756A1 KR 2016015345 W KR2016015345 W KR 2016015345W WO 2018110756 A1 WO2018110756 A1 WO 2018110756A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood glucose
atp
electrical energy
blood
battery module
Prior art date
Application number
PCT/KR2016/015345
Other languages
English (en)
Korean (ko)
Inventor
박영래
박동휘
Original Assignee
(재)대구포교성베네딕도수녀회
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (재)대구포교성베네딕도수녀회 filed Critical (재)대구포교성베네딕도수녀회
Publication of WO2018110756A1 publication Critical patent/WO2018110756A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/053—Measuring electrical impedance or conductance of a portion of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue

Definitions

  • the present invention relates to an Adenosine TriPhosphate (ATP) -based blood glucose meter, and more particularly, to a blood glucose meter that provides a blood glucose level to be inserted into the body, and utilizes ATP in the body as an electric energy source for driving the blood glucose level.
  • ATP Adenosine TriPhosphate
  • Diabetes a typical adult disease, is currently occurring at about 5% of the population, and the incidence rate is gradually increasing.
  • diabetes is a disease that absolutely requires self-management because it has the characteristics of a chronic disease that can not be cured once invented.
  • self-management refers to measuring blood sugar and managing blood glucose with blood collected at the fingertips of the diabetic patients themselves by using a blood glucose meter that changes according to daily food intake, activity level, drugs or insulin therapy.
  • Invasive blood glucose measurement is performed by applying a glycosylase to the end of a strip to measure blood glucose through an enzyme reaction. That is, when blood is collected from a finger or the like and contacted with an enzyme-fixed strip, blood glucose reacts with the enzyme.
  • the invasive blood glucose measurement method has a disadvantage in that the blood collection process is absolutely necessary, the blood collection site is changed, and the blood glucose measurement is difficult to be completely irrelevant according to the proficiency of the blood collection method. And fundamentally, there is a great difficulty in accurately measuring changes in blood glucose concentrations by non-continuous measurements. It also has the disadvantage that it is extremely difficult to measure blood glucose during sleep time.
  • the invasive blood glucose sensor had a limited lifespan due to the limitation of the battery capacity of the sensor.
  • the present inventors have provided an invasive blood glucose meter, but once inserted into the body has been invented a blood glucose meter that can be driven permanently without replacing the battery.
  • One technical problem to be solved by the present invention is to provide an invasive blood glucose meter in the body, to provide a blood glucose meter utilizing the ATP in the body as a power.
  • Another technical problem to be solved by the present invention is to provide a blood glucose meter forcibly consuming blood sugar when the body blood sugar is high.
  • the technical problem to be solved by the present invention is not limited to the above.
  • the present invention provides an ATP-based blood glucose meter.
  • ATP-based blood glucose meter is inserted into the body, a blood glucose measurement module for measuring blood glucose and inserted into the body, to produce electrical energy based on the substance in the body, the produced electrical energy is the blood sugar It may be made by including a biological battery module for supplying to the measurement module.
  • the bio battery module includes an anode electrode, an electrolyte, and a cathode electrode on which an enzyme is formed, and when the body substance is glucose and ATP, the enzyme is glucose 6-phosphoate dehydro. It may be genase.
  • the anode electrode may generate NADH through the enzyme, and oxidize the generated NADH to produce the electrical energy.
  • the blood sugar measuring module may measure the blood glucose level in the body based on the amount of electrical energy generated from the substance in unit time.
  • the blood glucose measurement module may measure a blood glucose level based on a difference in impedance.
  • the apparatus may further include a controller configured to control at least one of the blood sugar measuring module and the bio battery module, wherein the controller forcibly maintains the electric energy production in the body when the measured blood glucose level is greater than or equal to a reference value. Can reduce blood sugar levels.
  • the apparatus may further include a controller configured to control at least one of the blood sugar measuring module and the bio battery module, wherein the controller may change the blood sugar measuring method based on the amount of electrical energy stored in the bio battery module. Can be.
  • ATP-based blood glucose meter is inserted into the body, the blood sugar measuring module for measuring blood sugar and inserted into the body, supplying electrical energy to the blood sugar measuring module, the electrical energy based on the substance in the body It may include a bio-battery module for producing, storing and supplying the blood glucose measurement module.
  • the present invention since it can be self-filling based on the substance in the body can improve the ease of use of the body-insertable blood glucose meter.
  • FIG. 1 is a diagram illustrating an environment of using an ATP-based blood glucose meter according to an exemplary embodiment of the present invention.
  • Figure 2 shows a block diagram of an ATP-based blood glucose meter according to an embodiment of the present invention.
  • 3 is a diagram for explaining conversion between ATP and ADP.
  • FIG. 4 is a view for explaining a bioenergy module according to an embodiment of the present invention.
  • FIG. 5 is a view for explaining an example of driving the ATP-based blood glucose meter according to an embodiment of the present invention.
  • FIG. 6 is a view for explaining another driving example of the ATP-based blood glucose meter according to an embodiment of the present invention.
  • first, second, and third are used to describe various components, but these components should not be limited by these terms. These terms are only used to distinguish one component from another. Thus, what is referred to as a first component in one embodiment may be referred to as a second component in another embodiment.
  • first component in one embodiment may be referred to as a second component in another embodiment.
  • second component in another embodiment.
  • Each embodiment described and illustrated herein also includes its complementary embodiment.
  • the term 'and / or' is used herein to include at least one of the components listed before and after.
  • connection is used herein to mean both indirectly connecting a plurality of components, and directly connecting.
  • An ATP-based blood glucose meter (hereinafter, referred to as a blood glucose meter) according to an embodiment of the present invention may be inserted into a body to measure blood glucose in the body.
  • the blood glucose meter may be an energy source of a substance in the body, for example, ATP, which is an energy storage unit in the body. Accordingly, once the blood glucose meter according to an embodiment of the present invention is inserted into the body, blood glucose may be measured permanently without having to replace a battery.
  • FIG. 1 is a view illustrating an environment of using an ATP-based blood glucose meter according to an embodiment of the present invention
  • FIG. 2 is a block diagram of an ATP-based blood glucose meter according to an embodiment of the present invention.
  • the blood glucose meter 100 may be inserted into a portion of the body.
  • the blood glucose meter 100 may have various insertion positions. ATP is generated in the mitochondria in the cell, and particularly active in muscle cells. Therefore, the blood glucose meter 100 may be inserted into the muscle region. In addition, ATP can migrate along blood vessels. Therefore, the blood glucose meter 100 may be inserted at a position where blood flow is easy and an insertion procedure is easy and does not affect body movement. For example, the blood glucose meter 100 may be inserted into the back of the hand and the arm.
  • Blood sugar meter 100 may communicate with the external electronic device (300).
  • the blood glucose meter 100 may receive a command, for example, a blood sugar meter control command, from the external electronic device 300 and operate accordingly.
  • the blood glucose meter 100 may provide a blood sugar measurement result to the external electronic device 300.
  • the blood glucose meter 100 may transmit information about an operation status of the blood glucose meter 100, for example, an error occurrence state, to the external electronic device 300.
  • the blood glucose meter 100 according to an embodiment of the present invention will be described in more detail with reference to FIG. 2.
  • the blood glucose meter 100 may include at least one of a blood sugar measuring module 110, a bio battery module 120, a communication unit 140, and a controller 150.
  • a blood sugar measuring module 110 may be separate components, but in some cases, the blood sugar measuring module 110 and the bio battery module 120 may be integrally formed.
  • the blood sugar measuring module 110 and the bio battery module 120 may be integrally formed.
  • the blood sugar measuring module 110 performs a sensor function for measuring blood sugar in the body, and may measure blood sugar in various ways.
  • the blood sugar measuring module 110 may measure blood sugar based on an impedance difference. More specifically, a very small change in blood glucose results in a decrease in sodium ions and an increase in potassium ions in red blood cells and induces cell membrane reactions. Since the specific reaction between blood and tissue cells is changed by blood glucose, the electrolyte-equilibrium between the cell membranes changes, resulting in a change in membrane permeability, conductivity, and junction polarization (Maxwell-Wagner effect). In other words, the change in blood glucose changes the dielectric properties of skin and subcutaneous tissue and changes the dielectric spectrum which can be measured by impedance. Blood sugar itself does not affect the dielectric spectrum present in the MHz frequency band, but instead it can be converted into a blood glucose level using impedance spectroscopy.
  • the blood sugar measuring module 110 may measure blood glucose through the tissue fluid around the blood sugar measuring module 110.
  • the blood sugar measuring module 110 may measure blood sugar based on the amount of electrical energy generated from the ATP. More specifically, the blood glucose measurement module 110 may measure blood glucose based on the amount of electrical energy generated from ATP per unit time. In this case, the blood glucose measurement module 110 may be integrally formed with the biological battery module 120 to be described later.
  • the biological battery module 120 may be inserted into the body to supply electrical energy to the blood sugar measuring module 110. To this end, the biological battery module 120 may produce, store, and supply electrical energy to the blood glucose measurement module 110 based on ATP in the body. A detailed description of the biological battery module 120 will be described later with reference to FIGS. 3 and 4.
  • the communication unit 140 may perform a function of communicating with the external electronic device 300. As described above, the communication unit 140 may transmit information on the operation state of the blood glucose meter 100 and / or information on a blood sugar measurement result to the external electronic device 300. In addition, the communication unit 140 may receive a signal, for example, a command signal from the external electronic device 300. The communication unit 140 may provide the received command signal to the controller 150 to be described later.
  • the communication unit 140 may include at least one module of Bluetooth, Radio Frequency Identification (RFID), Infrared Data Association (IrDA), UltraWideband (UWB), and ZigBee.
  • RFID Radio Frequency Identification
  • IrDA Infrared Data Association
  • UWB UltraWideband
  • ZigBee ZigBee
  • the controller 150 may control the blood glucose meter 100 overall. For example, the controller 150 may measure blood sugar periodically / non-periodically through the blood sugar measuring module 110. The controller 150 may store the blood glucose measurement result as a database in units of time. The controller 150 may receive electric energy required through the bio battery module 120. In addition, the controller 150 may instruct the bio battery module 120 to produce and store electrical energy, and to supply the stored electrical energy to the blood sugar measuring module 110 and / or the communication unit 140. Can be lowered.
  • the controller 150 is hardware-specific application specific integrated circuits (ASICs), digital signal processors (DSPs), digital signal processing devices (DSPDs), programmable logic devices (PLDs), field programmable gate arrays (FPGAs), and processors (processors).
  • ASICs application specific integrated circuits
  • DSPs digital signal processors
  • DSPDs digital signal processing devices
  • PLDs programmable logic devices
  • FPGAs field programmable gate arrays
  • processors processors
  • the controller may be implemented using at least one of controllers, microcontrollers, microprocessors, and electrical units for performing functions.
  • the memory unit 152 may store a program for the operation of the controller 150, and store the blood sugar measurement result as a database.
  • the memory unit 152 may include a flash memory type, a hard disk type, a multimedia card micro type, a card type memory (for example, SD or XD). Memory, etc.), random access memory (RAM), static random access memory (SRAM), readonly memory (ROM), electrically erasable programmable readonly memory (EEPROM), programmable readonly memory (PROM) magnetic memory, magnetic disk, It may include at least one type of storage medium of the optical disk.
  • FIG 3 is a view for explaining the conversion of ATP and ADP
  • Figure 4 is a view for explaining a bioenergy module according to an embodiment of the present invention.
  • the biological battery module 120 may utilize ATP (adenosine triphosphate) in the body as an energy source.
  • ATP adenosine triphosphate
  • FIG. 3 for a detailed description of ATP, ATP may be defined as a compound in which three phosphoric acids bind structurally to adenine and ribose. At this time, phosphoric acid and phosphoric acid may be made of a high energy phosphoric acid bond.
  • ADP adenosine diphosphate
  • inorganic phosphate high energy phosphate bonds are broken and can release energy.
  • the bio battery module 120 may include at least one of a cathode 122, an anode 124, an enzyme 126, and an electrolyte 128.
  • a cathode 122 may include at least one of a cathode 122, an anode 124, an enzyme 126, and an electrolyte 128.
  • Electrons generated at the anode 124 may be provided to the cathode 122 along an external path.
  • the protons generated at the anode 124 may move to the cathode 122 through the electrolyte 128.
  • the enzyme 126 may be provided on the anode 124 to perform a function of generating protons and electrons from the body material.
  • the enzyme 126 may comprise hexokinase.
  • the enzyme 126 may be comprised of, for example, glucose 6-phosphate dehydrogenase (G6PDH).
  • the enzyme 126 may further include at least one substance of vitamin K3 and benzyl viologen. Specific functions of the material constituting the enzyme 126 will be described later.
  • the electrolyte 128 may provide a movement path such that protons generated from the anode 124 are transferred to the cathode 122.
  • the cathode 122 and the anode 126 may also be provided in the Y axis direction in parallel with the blood while the blood flows in the Y axis direction.
  • the electrode directions of the cathode 122 and the anode 126 may be different directions.
  • the anode 126 may be provided with a substance in the body for generating electrical energy in the blood.
  • glucose and ATP may be provided to the anode 126.
  • hexokinase among the enzymes 126 provided in the anode 126 may convert the glucose and ATP into G6P (glucose 6-phosphate) and ADP.
  • the glucose 6-phosphate dehydrogenase (G6PDH) in the enzyme 126 may then convert G6P (glucose 6-phosphate) to NADH and hydrogen protons.
  • vitamin K3 or benzyl viologen in the enzyme 126 may convert NADH to NADH + and e-.
  • protons and electrons can be generated from the body material.
  • the biological battery module 126 may generate and store electrical energy from a substance in the body.
  • the biological battery module 126 may further include a blocking film (not shown) to control the amount of the body material provided to the anode 124.
  • Method of operation of the biological battery module that is, the body material to be used, the enzyme for the body material is not limited to this, of course, it can be applied differently.
  • the battery module 120 according to the exemplary embodiment of the present invention has been described above with reference to FIGS. 3 and 4.
  • a driving method of the blood glucose meter 100 according to an exemplary embodiment of the present invention will be described with reference to FIGS. 5 and 6.
  • the ATP consumption may be variably controlled according to the blood glucose level.
  • an electrical energy production step (S110) through a bio battery module may be performed. And continuing the electrical energy production through the bio battery module (S130).
  • each step will be described in detail.
  • step S110 electrical energy production through the bio battery module may be performed.
  • the controller 150 may command electric energy production through the bio battery module 120.
  • the command of the controller 150 may be according to an algorithm of the controller 150 or may be a command obtained through the external electric device 300.
  • the biological battery module 120 may produce electrical energy based on ATP, as described above with reference to FIGS. 3 and 4.
  • step S120 it may be determined whether the electrical energy production amount exceeds a predetermined criterion. This is to take advantage of the fact that since electrical energy is produced based on glucose and ATP, the amount of electrical energy production is closely related to blood glucose levels.
  • the controller 150 may store the electrical energy produced by the bio battery module 120 in the memory unit 152 as a current and / or a voltage per unit time.
  • the controller 150 may determine whether the magnitude of the current and / or voltage produced per unit time exceeds a predetermined criterion.
  • the predetermined criterion may be a reference value set by a medical professional, a diet professional, or the like.
  • the predetermined criterion may correspond to the blood glucose allowance based on an event such as time or before / after meals. More specifically, when the allowed blood sugar level before meals is A1, the predetermined criterion may be A1? Corresponding to A1. In the same way, if the allowed blood glucose level after a meal is A2, the predetermined criterion may be A2? Corresponding to A2.
  • the controller 150 may determine whether the electrical energy produced through the bio battery module 120 exceeds a predetermined standard. If the electrical energy current and / or voltage produced per unit time exceeds a predetermined criterion, it may mean that the blood glucose is higher than the normal range. More specifically, the blood sugar level A1 allowed before meals, whereas when the electrical energy current and / or voltage produced per unit time exceeds A1 ?, it may mean that the blood sugar is higher than the normal range. In addition, the blood sugar A2 allowed after a meal, whereas the electrical energy current and / or voltage produced per unit time exceeds A2 ?, it may mean that the blood sugar is higher than the normal range.
  • step S130 electrical energy production through the bio battery module may be continued.
  • the controller 150 may continue to produce electrical energy through the bio-battery module 130 when the amount of electrical energy production exceeds a predetermined standard.
  • step S120 If the electrical energy production amount is less than or equal to a predetermined criterion in step S120, it may enter a standby state.
  • blood sugar can be forcibly consumed while preventing the risk of abnormally decreasing blood sugar.
  • FIG. 6 is a view for explaining another driving example of the ATP-based blood glucose meter according to an embodiment of the present invention.
  • a variable blood glucose measurement method may be provided in consideration of the remaining amount of the bio battery module.
  • the blood sugar measuring module 110 is a module for measuring blood sugar based on an impedance difference.
  • step S210 it may be determined whether the storage energy of the bio battery module is equal to or less than a reference value. That is, the controller 150 may determine whether the electrical energy stored in the biological battery module 120 is equal to or less than a reference value. In other words, the controller 150 may determine whether the remaining amount of the electric energy stored in the biological battery module 120 is insufficient or sufficient. According to the determination result, step S220 may be performed when the remaining amount of the stored electrical energy is equal to or less than a predetermined reference value, and blood glucose may be measured in a different manner from step S220 when the residual amount of stored electrical energy is equal to or more than the predetermined reference value.
  • the blood sugar level may be estimated through the electrical energy production amount of the bio battery module.
  • Step S220 may be implemented in a situation where the biological battery module 120 may be discharged.
  • the controller 150 may estimate the blood glucose level based on the amount of electrical energy produced per unit time when the remaining amount of the bio battery module 120 is less than or equal to a predetermined reference value. As a result, continuous blood glucose measurement can be performed while preventing discharge.
  • step S230 the blood glucose level may be measured in a different manner from step S220.
  • Step S230 may be implemented in a situation in which a sufficient amount of charge of the biological battery module 120 is sufficient and thus more accurate blood sugar measurement is required.
  • the controller 150 may supply the electrical energy stored in the biological battery module 120 to the blood sugar measuring module 110 to measure blood sugar through the blood sugar measuring module 110.
  • the blood glucose measurement method may be variably controlled in consideration of the battery remaining amount.
  • the blood glucose meter and driving examples thereof according to an embodiment of the present invention have been described above with reference to FIGS. 1 to 6.
  • the blood glucose meter according to an embodiment of the present invention described above since it is possible to charge itself based on the substance in the body in a state of invading the body, it may provide various advantages.
  • patients who take anti-thrombosis / coagulants at all times, patients with hemophilia, and patients with weak immunity have difficulty in performing blood glucose measurement surgery.
  • the blood glucose meter according to an embodiment of the present invention does not require an additional operation for charging the battery after the initial insertion operation, the convenience of blood sugar measurement may be greatly increased.
  • the blood glucose meter according to an embodiment of the present invention can be self-charged, the size of the battery can be miniaturized. Therefore, it is applicable to newborns and infants.
  • the blood glucose meter according to an embodiment of the present invention may have a self-learning function. For example, by storing the blood sugar value measured by the blood glucose meter according to the exemplary embodiment of the present invention and the blood sugar value measured by the invasive method together with the memory unit, the blood sugar value measured by the blood glucose meter can be appropriately corrected.
  • Blood glucose meter according to an embodiment of the present invention can be applied to the medical and health field, for example, human invasive blood glucose meter.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Emergency Medicine (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un dispositif de surveillance de glycémie basé sur l'adénosine triphosphate (ATP). Selon un mode de réalisation de la présente invention, le dispositif de surveillance de glycémie basé sur l'ATP peut comprendre : un module de surveillance de glycémie introduit dans le corps et destiné à surveiller la glycémie ; et un module de bio-batterie qui est introduit dans le corps, qui est destiné à générer de l'énergie électrique sur la base d'un matériau in vivo, et qui est destiné à alimenter le module de surveillance de glycémie en énergie électrique générée.
PCT/KR2016/015345 2016-12-13 2016-12-27 Dispositif de surveillance de glycémie basé sur l'adénosine triphosphate WO2018110756A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160169228A KR101902078B1 (ko) 2016-12-13 2016-12-13 ATP(Adenosine TriPhosphate) 기반 혈당계
KR10-2016-0169228 2016-12-13

Publications (1)

Publication Number Publication Date
WO2018110756A1 true WO2018110756A1 (fr) 2018-06-21

Family

ID=62558694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/015345 WO2018110756A1 (fr) 2016-12-13 2016-12-27 Dispositif de surveillance de glycémie basé sur l'adénosine triphosphate

Country Status (2)

Country Link
KR (1) KR101902078B1 (fr)
WO (1) WO2018110756A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007232378A (ja) * 2006-02-27 2007-09-13 Sumitomo Electric Ind Ltd バイオセンサシステム及びその測定器
JP2009536441A (ja) * 2006-05-05 2009-10-08 スペンサー ジェイ ジー エップス 埋め込み型ボルタ電池
KR20160013596A (ko) * 2014-07-28 2016-02-05 김성우 체내 혈당 측정장치 및 방법
KR20160015197A (ko) * 2013-06-05 2016-02-12 이 헹 퍼시벌 장 세포-비함유 합성 효소적 경로를 이용한 당의 전기로의 완전 산화
KR20160108531A (ko) * 2014-01-16 2016-09-19 더말 디바이시스 인코퍼레이티드 삽입 가능한 센서 및 그러한 센서를 위한 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007232378A (ja) * 2006-02-27 2007-09-13 Sumitomo Electric Ind Ltd バイオセンサシステム及びその測定器
JP2009536441A (ja) * 2006-05-05 2009-10-08 スペンサー ジェイ ジー エップス 埋め込み型ボルタ電池
KR20160015197A (ko) * 2013-06-05 2016-02-12 이 헹 퍼시벌 장 세포-비함유 합성 효소적 경로를 이용한 당의 전기로의 완전 산화
KR20160108531A (ko) * 2014-01-16 2016-09-19 더말 디바이시스 인코퍼레이티드 삽입 가능한 센서 및 그러한 센서를 위한 방법
KR20160013596A (ko) * 2014-07-28 2016-02-05 김성우 체내 혈당 측정장치 및 방법

Also Published As

Publication number Publication date
KR101902078B1 (ko) 2018-09-27
KR20180067853A (ko) 2018-06-21

Similar Documents

Publication Publication Date Title
CN104903738B (zh) 具有安全系统的低功耗电池组
US8550997B2 (en) Sensor and monitor system
EP2877093B1 (fr) Fonctionnalité de dispositif médical manuel sans batterie
US9370322B2 (en) Modular docking station
WO2020218741A1 (fr) Dispositif de détection de signaux biométriques en forme d'anneau
CN102781323A (zh) 身体参数传感器和监控器接口
US9689753B2 (en) Handheld analyte meter with recharging control for improved analyte testing
CN106921211A (zh) 用于医疗器械的电源管理系统及其工作方法
WO2020032382A1 (fr) Appareil pour commander le fonctionnement d'un testeur continu de la glycémie
WO2018110756A1 (fr) Dispositif de surveillance de glycémie basé sur l'adénosine triphosphate
WO2013069895A1 (fr) Lecteur de glycémie personnel et méthode de détection d'une mesure anormale l'utilisant
TW202227848A (zh) 用於醫療裝置中的低電池電壓閾值及電壓下降之偵測的溫度補償之方法及設備
WO2019160255A1 (fr) Dispositif de mesure d'informations biométriques continue faisant appel à des informations d'utilisation de capteur mémorisées dans une mémoire
CN102119860B (zh) 非侵入式血糖量测系统和测量方法
CN113364079A (zh) 可穿戴医疗装置
EP3873341B1 (fr) Circuit de commutation pour un dispositif de contrôle de fluide
US10620149B2 (en) Sensor detection pads with integrated fuse
KR101869870B1 (ko) 무정지 보장형 스마트패치
CN204086109U (zh) 一种便携式糖化血红蛋白分析仪
CN1866009B (zh) 生物传感器
JP2011089781A (ja) 生体試料検出装置
CN217525122U (zh) 一种微型传感器专用推送装置的底座组件
CN105246546A (zh) 用于外部除颤器的自动功率管理
CN108903934A (zh) 低功耗心电监测装置及方法
CN211292699U (zh) 一种保护伤口的血糖试纸

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16923779

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16923779

Country of ref document: EP

Kind code of ref document: A1